STANDARD BIOTOOLS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.93 USD | +0.52% |
|
-10.23% | -12.67% |
| 05-20 | Standard BioTools Receives Shareholder Proposal from Madryn Asset Management | CI |
| 05-08 | Tranche Update on Standard BioTools Inc.'s Equity Buyback Plan announced on March 1, 2024. | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.67% | 714M | C- | ||
| +6.37% | 216B | B | ||
| +10.21% | 189B | B- | ||
| +28.22% | 153B | B- | ||
| +34.42% | 114B | A- | ||
| +0.99% | 63.2B | A- | ||
| +19.21% | 54.78B | B+ | ||
| +0.13% | 48.47B | B+ | ||
| -4.16% | 38.88B | A | ||
| +2.39% | 36.14B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LAB Stock
- Ratings Standard BioTools Inc.
